B-cell lymphoma 3 protein (BCL3)

B-cell lymphoma 3 protein (BCL3) is an atypical member of the IκB protein family that acts primarily as a nuclear transcription coactivator, modulating the activity of the NF-κB signaling pathway. BCL3 contains ankyrin repeats and can either inhibit or activate transcription of NF-κB target genes by binding to p50 and p52 NF-κB homodimers, recruiting a range of transcriptional co-regulators that fine-tune gene expression. BCL3 is strictly controlled by phosphorylation, ubiquitination, and its own induced gene expression, allowing it to respond dynamically in processes such as cell proliferation, immune regulation, inflammation, apoptosis, and lipid metabolism. Dysregulation is implicated in a variety of diseases, most notably B-cell leukemias, lymphomas, autoimmune diseases, chronic inflammation, and metabolic syndrome. BCL3 has been identified as a proto-oncogene due to its chromosomal translocation and oncogenic activity in blood cancers. Its dual role in regulating NF-κB function means it may act as both a pro- and anti-inflammatory factor depending on cellular and signaling context[1][2][3].

Other names

B-cell lymphoma 3 proteinBCL4D19S37Proto-oncogene BCL3B-cell leukemia/lymphoma 3chronic lymphatic leukemia proteinB cell CLL/lymphoma 3BCL-3